Andrew Aromando bought $25k of ONCY
Chief Business Officer at ONCOLYTICS BIOTECH INC. 29,600 shares at an average of $0.86, traded Feb 11, 2026, filed Feb 13, 2026.
Score components
- +15RoleOfficer
- +5Trade size$25k at market
- +10Relative to holdingsHoldings up 116%
- 0Price contextNo price history yet
- +15Cluster9 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-006541, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | POpen-market purchase Common Shares | +29,600 | $0.86 | $25k | 55,100 | Feb 13, 2026 |
Related signals
Other insiders at ONCOLYTICS BIOTECH INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | ONCOLYTICS BIOTECH INC | Jared Kelly Chief Executive Officer | $4,848 5,050 shares | +5% | |
| 29Weak | ONCOLYTICS BIOTECH INC | James T. Parsons director | $10k 10,000 shares | +31% | |
| 45Moderate | ONCOLYTICS BIOTECH INC | Patricia S Andrews director | $30k 35,400 shares | +83% | |
| 36Weak | ONCOLYTICS BIOTECH INC | Deborah Margaret Brown director | $21k 25,000 shares | +29% | |
| 33Weak | ONCOLYTICS BIOTECH INC | Allison Hagerman VP, Product Development | $8,298 10,000 shares | +10% | |
| 30Weak | ONCOLYTICS BIOTECH INC | Thomas Charles Heineman Chief Medical Officer | $10k 12,132 shares | +4% | |
| 51Moderate | ONCOLYTICS BIOTECH INC | Jared Kelly Chief Executive Officer | $30k 35,100 shares | +47% | |
| 37Weak | ONCOLYTICS BIOTECH INC | Kirk Look Chief Financial Officer | $10k 12,000 shares | +4% | |
| 38Weak | ONCOLYTICS BIOTECH INC | Wayne Pisano director | $25k 30,000 shares | +6% | |
| 50Moderate | ONCOLYTICS BIOTECH INC | Bernd R. Seizinger director | $83k 100,000 shares | +21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.